Brainstorm to Announce Third Quarter Financial Results And Provi - Erie News Now | WICU & WSEE in Erie, PA

Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

SOURCE BrainStorm Cell Therapeutics Inc.

Conference Call and Live Webcast at 8:30am Eastern Time

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 3, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and nine months ended September 30, 2017, and provide important corporate updates, on Tuesday, October 17.

Logo - hi-res

Tuesday, October 17, 2017 @ 8:30am Eastern Time

Toll Free:

888-395-3237

Israel Investors:

1 80 924 5905

International:

719-325-2349

Conference ID:

4131959

Webcast:

http://public.viavid.com/index.php?id=126580

Replays, available through October 31, 2017

Toll Free:

844-512-2921

International:

412-317-6671

Conference ID:

4131959

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka
Chief Business Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-to-announce-third-quarter-financial-results-and-provide-corporate-updates-on-tuesday-october-17-300530261.html

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
WICU FCC Filing
WSEE FCC Filing
Share:
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2017 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 - info@wicu12.com